Lantern Pharma Inc. (LTRN) News

Lantern Pharma Inc. (LTRN): $6.13

-0.37 (-5.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LTRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 423

in industry

Filter LTRN News Items

LTRN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LTRN News Highlights

  • LTRN's 30 day story count now stands at 4.
  • Over the past 20 days, the trend for LTRN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about LTRN are DRUG, COCP and FL.

Latest LTRN News From Around the Web

Below are the latest news stories about Lantern Pharma Inc that investors may wish to consider to help them evaluate LTRN as an investment opportunity.

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at the University

Yahoo | February 15, 2022

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Lantern Pharma (LTRN)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and Lantern Pharma (LTRN – Research Report) with bullish sentiments. Cocrystal Pharma (COCP) In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma, with a price target of $5.00. The company's shares closed last Monday at $0.55, close to its 52-week low of $0.47. According to TipRanks.

Brian Anderson on TipRanks | February 8, 2022

Sanders Morris Harris Llc Buys Roth CH Acquisition V Co, The Walt Disney Co, Mastercard Inc, ...

Investment company Sanders Morris Harris Llc (Current Portfolio) buys Roth CH Acquisition V Co, The Walt Disney Co, Mastercard Inc, Elanco Animal Health Inc, Hawks Acquisition Corp, sells Visa Inc, Endeavor Group Holdings Inc, Endeavor Group Holdings Inc, FedEx Corp, Splunk Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sanders Morris Harris Llc.

Yahoo | February 2, 2022

RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28

ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, beginning at 9:15 a.

Yahoo | January 26, 2022

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development today announced that the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation and Orphan Drug Designation for the company's drug candidate LP-184 for the treatment of pediatric patients with ATRT. LP-184 is being pursued as a potent

Yahoo | January 24, 2022

LTRN: Multiple Collaborations Illuminating Way Forward

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Since Our Last Update Lantern Pharma, Inc. (NASDAQ:LTRN) has promulgated several updates since our report on the company’s third quarter 2021 results. In its latest corporate presentation, Lantern also updated the number of datapoints that have been accumulated on its Response Algorithm for Drug Positioning & Rescue

Yahoo | January 20, 2022

H.C. Wainwright Thinks Lantern Pharma’s Stock is Going to Recover

In a report released today, Michael King from H.C. Wainwright reiterated a Buy rating on Lantern Pharma (LTRN – Research Report), with a price target of $34.00. The company's shares closed last Tuesday at $6.58, close to its 52-week low of $6.56. According to TipRanks.com, King is a 4-star analyst with an average return of 15.3% and a 47.7% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lantern Pharma with a $29.00 average price target.

Catie Powers on TipRanks | January 18, 2022

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration and research agreement with The Danish Cancer Society Research Center (DCRC) to support clinical development of Lantern's acylfulvene class drug candidates, LP-100 and LP-184, as well as the development of improved diagnostic methods to i

Yahoo | January 18, 2022

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has expanded its collaboration agreement with the Developmental Therapeutics Branch (DTB) of the National Cancer Institute (NCI) of the National Institutes of Health. The expansion of this collaboration comes after identifying several gene signatures

Yahoo | January 12, 2022

Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. The presentation will be conducted as a fireside chat hosted by H.C

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.671 seconds.